Press release: sanofi to acquire provention bio, adding to portfolio tzield, the first disease-modifying treatment for the delay of stage 3 type 1 diabetes (t1d)

Sanofi to acquire proventio n bio, adding to portfolio tzield, the first disease-modifying treatment for the delay of stage 3 type 1 diabetes (t1d)
PRVB Ratings Summary
PRVB Quant Ranking